Aura Biosciences (AURA) EBITDA (2020 - 2026)

Aura Biosciences (AURA) has 7 years of EBITDA data on file, last reported at -$34.9 million in Q1 2026.

• Quarterly EBITDA fell 20.08% year-over-year to -$34.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118.6 million (down 15.35% YoY) and the FY2025 annual result came in at -$112.8 million, down 17.35% from the prior year.
• EBITDA slipped to -$34.9 million in Q1 2026, from -$27.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$12.8 million in Q1 2022 to a low of -$34.9 million in Q1 2026.
• A 5-year average of -$22.9 million and a median of -$22.8 million in 2024 frame the typical range for EBITDA.
• Annual changes were most pronounced in 2022 — EBITDA plunged 116.15% — and 2025, when it advanced 2.05%.
• Tracing AURA's EBITDA over 5 years: stood at -$17.6 million in 2022, then plunged by 40.71% to -$24.8 million in 2023, then fell by 12.2% to -$27.8 million in 2024, then climbed by 2.05% to -$27.2 million in 2025, then dropped by 28.01% to -$34.9 million in 2026.
• The last three EBITDA figures came in at -$34.9 million (Q1 2026), -$27.2 million (Q4 2025), and -$27.9 million (Q3 2025), per Business Quant data.